US20120003305A1 - Oral Dosage Forms Of Bendamustine - Google Patents
Oral Dosage Forms Of Bendamustine Download PDFInfo
- Publication number
- US20120003305A1 US20120003305A1 US13/132,263 US200913132263A US2012003305A1 US 20120003305 A1 US20120003305 A1 US 20120003305A1 US 200913132263 A US200913132263 A US 200913132263A US 2012003305 A1 US2012003305 A1 US 2012003305A1
- Authority
- US
- United States
- Prior art keywords
- bendamustine
- pharmaceutical composition
- minutes
- composition according
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N CN1C2=CC=C(N(CCCl)CCCl)C=C2N=C1CCCC(=O)O Chemical compound CN1C2=CC=C(N(CCCl)CCCl)C=C2N=C1CCCC(=O)O YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- BPLHFEZJKLCZQG-UHFFFAOYSA-N CN1C2=CC=C(N(CCO)CCCl)C=C2N=C1CCCC(=O)O.CN1C2=CC=C(N(CCO)CCO)C=C2N=C1CCCC(=O)O.CN1C2=CC=C(N3CCOCC3)C=C2N=C1CCCC(=O)O Chemical compound CN1C2=CC=C(N(CCO)CCCl)C=C2N=C1CCCC(=O)O.CN1C2=CC=C(N(CCO)CCO)C=C2N=C1CCCC(=O)O.CN1C2=CC=C(N3CCOCC3)C=C2N=C1CCCC(=O)O BPLHFEZJKLCZQG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to oral dosage forms comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof.
- Bendamustine (4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazo-2-yl]butanoic acid, a nitrogen mustard) is an alkylating agent with bifunctional alkylating activity. It corresponds to the following formula (I):
- Bendamustine appears to be free of any cross-resistance with other alkylating agents, which offers advantages in terms of chemotherapy for patients who have already received treatment with an alkylating agent.
- Bendamustine was initially synthesized in the German Democratic Republic (GDR).
- GDR German Democratic Republic
- the hydrochloric acid of bendamustine was the active ingredient in a commercial product available from 1971 to 1992 under the trade name Cytostasan®. Since that time, it has been marketed in Germany under the trade name Ribomustin® and has been widely used to treat chronic lymphocytic leukemia, non-Hodgkin's lymphoma and multiple myeloma.
- the marketed product contains a lyophilized powder of bendamustine hydrochloride which is reconstituted with water for injection yielding a concentrate. This is subsequently diluted with an aqueous solution of 0.9% sodium chloride resulting in the final solution for infusion. This final solution is administered to the patient by intravenous infusion over a period of about 30 to 60 minutes.
- US 2006/0128777 A1 describes methods for treating cancers, characterised by death-resistant cells and bendamustine-containing compositions in general.
- oral dosage forms which are capsules, tablets, pills, powders or granules, wherein the active compound may be admixed with at least one inert excipient, such as sucrose, lactose or starch.
- inert excipient such as sucrose, lactose or starch.
- specific compositions were not exemplified.
- Bendamustine hydrochloride is only sparingly soluble in water at a pH of 2.0 and is slightly or very slightly soluble in a range of organic solvents. A good solubility has been observed however in ethanol and methanol. Therefore it is not surprising that the oral bendamustine compositions, as investigated by Preiss et al. and Weber gave rise to relatively poor bioavailability results and a large inter-individual variability.
- compositions are suitable for oral administration and comprise bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which compositions apart from having a good stability also have an improved dissolution profile.
- FIG. 1 shows the mean plasma concentration vs. time curve obtained after administering bendamustine hydrochloride in the form of the prior art capsule (reference example 1) and the liquid filled hard capsule formulation of Example 2 to dogs. It is apparent from FIG. 1 that the liquid filled hard capsule formulation provides for a higher maximum concentration of bendamustine, as compared with the prior art reference capsule formulation.
- FIG. 2 shows the mean plasma vs. time profile obtained after administering bendamustine hydrochloride in the form of the intravenous preparation, as marketed in Germany under the trademark Ribomustin®, and the liquid filled hard capsule formulation of example 2 to patients with cancer.
- the present invention relates to a pharmaceutical composition for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.
- a pharmaceutically acceptable excipient which is a non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.
- An embodiment is a pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof and a pharmaceutically acceptable excipient, which is a non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide, wherein the composition is suitable for oral administration by including it into a hard gelatine capsule.
- a pharmaceutically acceptable excipient which is a non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide
- a further embodiment is a pharmaceutical composition for oral administration in a solid dosage-form, which is a hard gelatine capsule, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof and a pharmaceutically acceptable excipient, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide and preferably selected from the group consisting of macrogol glycerol hydroxystearate, polyoxyl-35-castor oil and ethylene oxide/propylene oxide block copolymer (Pluronic® L44 NF or Poloxamer® 124), wherein the use of the specific non-ionic surfactant leads to a dissolution profile of at least 60% bendamustine dissolved after 20 minutes, 70% dissolved after 40 minutes and 80% dissolved after 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5
- a preferred embodiment is a pharmaceutical composition for oral administration in a solid dosage-form, which is a hard gelatine capsule, the composition comprising bendamustine hydrochloride and a pharmaceutically acceptable excipient, which is macrogol glycerol hydroxystearate, wherein the use of the specific non-ionic surfactant results in a dissolution of at least 60% bendamustine dissolved after 10 minutes, 70% after 20 minutes and 80% after 30 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5.
- the present invention is based on the surprising finding that stable compositions of bendamustine having a specific and desirable dissolution profile can be obtained by incorporating into the pharmaceutical composition certain non-ionic surfactants. It has been found that if a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide and preferably selected from the group consisting of macrogol glycerol hydroxystearate, polyoxyl-35-castor oil and ethylene oxide/propylene oxide block copolymer (Pluronic® L44 NF or Poloxamer® 124) is used as an excipient in a pharmaceutical composition comprising bendamustine or a pharmaceutically acceptable ester, a salt or a solvate thereof as an active ingredient, a particularly favourable profile of the composition with respect to stability and degradation products, dissolution, bioavailability and a reduced variability in bioavailability is achieved.
- the incorporation of the above-mentioned non-ionic surfactants in bendamustine-containing compositions results in a dissolution profile of at least 60% bendamustine dissolved after 20 minutes, 70% dissolved after 40 minutes and 80% dissolved after 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5 and preferably it results in a dissolution of at least 60% bendamustine dissolved after 10 minutes, 70% after 20 minutes and 80% after 30 minutes.
- esters with alkyl alcohols and sugar alcohols examples include C 1-6 -alkyl alcohols such as methanol, ethanol, propanol, isopropanol, butanol and tert-butanol.
- alkyl alcohols C 1-6 -alkyl alcohols such as methanol, ethanol, propanol, isopropanol, butanol and tert-butanol.
- sugar alcohols are mannitol, maltitol, sorbitol, erythritol, glycol, glycerol, arabitol, xylitol and lactitol.
- Preferred examples of the bendamustine esters are the ethyl ester, the isopropyl ester, the mannitol ester and the sorbitol ester, most preferred is the ethylester thereof.
- pharmaceutically acceptable salt thereof describes any pharmaceutically acceptable salt of bendamustine that administered to a patient (directly or indirectly) provides bendamustine. This term further comprises the pharmaceutically acceptable salt of a bendamustine ester. Nevertheless, it will be considered that the pharmaceutically non-acceptable salts also are included within the limits of this invention since these compounds can be useful in the preparation of pharmaceutically acceptable salts.
- pharmaceutically acceptable salts of bendamustine are synthesized from the corresponding compound that contains an acid or basic group, by conventional chemical methods.
- these salts are, for example, prepared by means of the reaction of free acidic or basic forms of these compounds in a stoichiometric amount with a corresponding base or acid in water or an organic solvent or a mixture of both.
- Nonaqueous media like ether, ethyl acetate, isopropanol or acetonitrile are generally preferred.
- acids which may be used for the salt formation of pharmaceutically acceptable salts of bendamustine include inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphuric, nitric, and phosphoric acids, and organic acids such as acetic, maleic, fumaric, citric, oxalic, succinic, tartaric, malic, lactic, methylsulphonic and p-toluenesulphonic acids.
- Pharmaceutically acceptable salts of bendamustine may be derived from either inorganic or organic bases to yield ammonium salts; alkali metal salts (lithium, sodium, potassium, etc.), alkaline earth salts like calcium or magnesium, aluminium salts, lower alkylamine salts like methylamine or ethylamine salts, lower alkyldiamine salts like ethylenediamine salts, ethanolamine, N,N-dialkyleneethanolamine, triethanolamine, and glucamine salts, as well as basic salts of amino acids.
- acid salts prepared from the hydrochloride, the hydrobromide, and the hydroiodide whereas the hydrochloride salt is the most preferred pharmaceutically acceptable salt of bendamustine.
- the pharmaceutically acceptable salts are produced by conventional techniques well-known in the art.
- the expression “pharmaceutically acceptable solvate thereof” describes any pharmaceutically acceptable solvate that, administered to a patient (directly or indirectly) provides bendamustine.
- This term further comprises the pharmaceutically acceptable solvate of a bendamustine ester.
- the solvate is a hydrate, a solvate with an alcohol such as methanol, ethanol, propanol, or isopropanol, a solvate with an ester such as ethyl acetate, a solvate with an ether such as methyl ether, ethyl ether or THF (tetrahydrofuran) or a solvate with DMF (dimethylformamide), of which a hydrate or a solvate with an alcohol such as ethanol is more preferred.
- a solvent for constituting the solvate is preferably a pharmaceutically acceptable solvent.
- the active ingredient in the invention's compositions is bendamustine or a pharmaceutically acceptable salt thereof. It is most preferred that the active ingredient is bendamustine hydrochloride.
- the dose of the active ingredient in the pharmaceutical composition may readily be determined by the skilled artisan depending on the patient's condition, sex, body weight, body surface area, or age, especially depending on the patient's body weight and body surface area. It is preferred that the daily dosage ranges from about 50 to about 1000 mg, preferably from about 100 to about 500 mg of the active ingredient.
- the daily dosage may be taken as a single dose or as multiple doses such as twice or three-times daily, most preferably as a single daily dose.
- the daily dose may be taken once a week or several times a week.
- the dosage form may contain the amount of a single daily dose or parts thereof. It is preferred that the dosage form of the present invention comprises about 10 to about 1000 mg, preferably about 25 to about 600 mg, more preferably about 50 to about 200 mg and most preferably about 100 mg of the active ingredient.
- non-ionic surfactant refers to an amphiphilic compound having a polar, hydrophilic group and a non-polar, lipophilic group or chain and wherein the hydrophilic and lipophilic properties of the compound are characterised by the so-called Hydrophilic-Lipophilic Balance (HLB) value.
- HLB Hydrophilic-Lipophilic Balance
- the non-ionic surfactant to be used for preparing the compositions of the present invention preferably has an HLB-value between 10 and 20 and preferably between 12 and 18.
- the non-ionic surfactant further has a melting point, pour point or melting range between 5° C. and body temperature (37° C.) and preferably between just below room temperature (20° C.) and body temperature.
- the material can be in a liquid or a semi-solid state at room temperature.
- the amphiphilic material is a carrier for the bendamustine active ingredient, which can be present in a dissolved form, a suspended form or partly in a dissolved and partly in a suspended form.
- non-ionic surfactants that are advantageously used for the preparation of the compositions according to the present invention are selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide/propylene oxide, provided the materials have the afore-mentioned HLB-value and melting point, pour point or melting range.
- the non-ionic surfactant is a polyethoxylated castor oil.
- a polyethoxylated castor oil is sold under the tradename Cremophor®. Cremophor® products of various purities and viscosities are produced and may be used in the present invention. In particular macrogol glycerol hydroxystearate (Cremophor® RH 40) and polyoxyl-35-castor oil (Cremophor® EL or Cremophor® ELP) can be used. Cremophor® ELP and Cremophor® EL are known as nonionic solubilizers and emulsifiers, produced by reacting castor oil with ethylene oxide in a molar ratio of 1 to 35.
- Macrogol glycerol hydroxystearate (commercially available as Cremophor® RH 40) is a semi-solid material at 25° C., having a viscosity range at the same temperature of 20-40 cps (as a 30% aqueous solution). It is known as a nonionic solubiliser and emulsifier. It is produced by reacting castor oil with ethylene oxide in a molar ratio of 1 to 45. Its HLB-value ranges from 14-16 and the melting range is from 20-28° C. In experiments it was shown that macrogol glycerol hydroxystearate can advantageously be used on its own for the preparation of compositions according to the present invention.
- Pluronic® block copolymers consist of ethylene oxide and propylene oxide blocks.
- the ethylene oxide units have a hydrophilic character whereas the propylene oxide units have a lipophilic character Variations in the number of hydrophilic ethylene oxide units and lipophilic propylene oxide units results in copolymers with a different molecular mass and different hydrophilic-lipophilic-balance (HLB).
- HLB hydrophilic-lipophilic-balance
- Examples of block copolymers of propylene oxide (“PEO”)-polypropylene oxide (“PPO”) meeting the requirements of the HLB-value and the melting point or pour point or melting range for making the compositions according to the present invention include the commercially available types Pluronic® L35, Pluronic® L 44, Pluronic® L64, Pluronic® P85 and Pluronic® P105.
- Pluronic® L44 is a preferred non-ionic surfactant.
- non-ionic surfactants are all liquids having a viscosity value which may be too low to avoid sedimentation of the bendamustine hydrochloride.
- the additional problem to be solved was to find an excipient or a combination of excipients that would allow for a total value for the viscosity of the mixture that would be high enough to avoid segregation of the bendamustine chloride when added to the mixture.
- compositions according to the present invention that contain a liquid non-ionic surfactant, advantageously further contain a viscosity improving agent.
- Suitable viscosity-improving agents include a powder such as colloidal silicon dioxide (commercially available under the trademark Aerosil®) or a semi-solid waxy material, such as lauroyl macrogol glycerides (commercially available under the trademark Gelucire® 44/14).
- the amount of the powder or the semi-solid material to be added to the liquid non-ionic surfactant depends on the viscosity of the liquid non-ionic surfactant. Different concentrations have been tested in order to find the minimum suitable amount of viscosity improving agent to be added to visually avoid sedimentation of the active ingredient.
- Typical relative concentrations of colloidal silicon dioxide to be added range from about 1% to about 8%, but are preferably as low as 1.7% or 2.0% in order not to have a negative impact on the dissolution characteristics of the active ingredient.
- Typical relative concentrations of lauroyl macrogol glycerides range from 5 to 50%, and are preferably about 10% and about 45%.
- compositions according to the present invention are disclosed in example 4 and comprise bendamustine hydrochloride in combination with:
- compositions of the present invention can include additional excipients, in particular protective agents, such as anti-oxidants and antimicrobial preservatives, e.g. methyl-, ethyl- and propylparaben, as illustrated in examples 1-3.
- protective agents such as anti-oxidants and antimicrobial preservatives, e.g. methyl-, ethyl- and propylparaben, as illustrated in examples 1-3.
- the antioxidant may be d-alpha tocopherol acetate, dl-alpha tocopherol, ascorbyl palmitate, butylated hydroxyanidole, ascorbic acid, butylated hydroxyanisole, butylated hydroxyquinone, butylhydroxyanisol, hydroxycoumarin, butylated hydroxytoluene, ethyl gallate, propyl gallate, octyl gallate, lauryl gallate, or mixtures thereof.
- the anti-oxidant is preferably added to compositions containing macrogol glycerol hydroxystearate or polyoxyl-35-castor oil.
- compositions according to the present invention are advantageously filled into a capsule, which can then easily be taken by the patient.
- capsules Two types of capsule are commonly used and are classified according to the nature and flexibility of the capsule shell: soft and hard capsules.
- Soft capsules are single unit solid dosage forms comprising a liquid or semi-solid fill. They are formed, filled and sealed in one operation using a rotary die process. They have been used as unit dose containers for liquids for many years, whereas hard capsules have conventionally been used for the delivery of solids in the form of powders, granulates and pellets.
- Hard capsules are single unit dosage forms, consisting of a cap and a body, which are manufactured separately and which are supplied empty for filling.
- Soft capsules are most commonly manufactured from gelatine, to which a plasticiser, usually glycerine or sorbitol, is added in addition to water. Also for hard capsules the most commonly used polymer is gelatine. An additional component is water, which acts as a plasticiser. This component however may be responsible for degradation of active ingredients, such as bendamustine hydrochloride. Therefore as an alternative hard capsules may be manufactured from hydroxypropylmethyl cellulose.
- Both soft and hard capsules in addition can include colouring agents and opacifiers.
- the preferred type of capsule for the compositions according to the present invention is the hard capsule and more in particular the hard gelatine capsule.
- the materials to be filled into the capsule are fluid at room temperature, which would avoid heating during the filling operation. Generally, heating could result in an easy degradation of the active component.
- fill formulations for hard capsules may be Newtonian liquids, such as oils, thixotropic or shear thinning gels or semi-solid matrix products that are filled at elevated temperatures and in which the active ingredient is either dissolved or suspended as a fine dispersion.
- any excipient or mixture of excipients can be used provided that the viscosity of the fill material confirms to the requirements of the filling process.
- the uniformity of capsule fill weights is important. Further fill formulations should not show stringing and should allow for a clean break from the dosing nozzle.
- compositions according to the present invention can be advantageously administered in hard gelatine capsules.
- the particular non-ionic surfactants selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide/propylene oxide, and in particular from the group consisting of macrogol glycerol hydroxystearate, polyoxyl-35-castor oil and Pluronic® L44 or Poloxamer® 124, if incorporating bendamustine or a pharmaceutically acceptable ester, salt, or solvate thereof, and after incorporation into hard gelatine capsules result in achieving a good stability, a good dissolution profile and a good bioavailability.
- Cremophor® A 25 ceteareth-25 or macrogol (25) cetostearyl ether
- Cremophor® A 6 ceteareth-6 and stearylalcohol or macrogol (6) cetostearyl ether
- the stability of an aqueous solution of bendamustine is strongly influenced by the pH. A significant hydrolytic decomposition of this compound is observed at pH values higher than about 5. At pH>5, the decomposition proceeds rapidly and the resulting content of by-products is high in this pH range.
- the main hydrolysis products are 4-[5-[(2-Chloroethyl)-(2-hydroxyethyl)amino]-1-methyl-benzimidazo-2-yl]-butanoic acid (HP1), 4-[5-[Bis(2-hydroxyethyl)amino]-1-methyl-benzimidazo-2-yl]-butanoic acid (HP2) and 4-(5-Morpholino-1-methylbenzimidazol-2-yl)-butanoic acid (HP3):
- Absorption of an orally administered drug usually happens from the stomach, the small intestine and/or the large intestine.
- the pH in the stomach is about 1 to 3.5, in the small intestine about 6.5 to 7.6, and in the large intestine about 7.5 to 8.0.
- compositions comprising bendamustine hydrochloride in a pharmaceutically acceptable excipient, which is a non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide, surprisingly show a fast dissolution, and in particular a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, and preferably of at least 60% in 10 minutes, 70% in 20 minutes and 80% in 30 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in an artificial gastric fluid.
- the artificial gastric fluid refers to a solution prepared by dissolving 2 g of sodium chloride in 1000 ml of water and then adjusting the pH to 1.5 ⁇ 0.05 with 5 N hydrochloric acid.
- the total time of a drug to pass the stomach to the small intestine is between about 20 minutes to 5 hours, usually between about 30 minutes to 3 hours.
- pharmaceutical compositions according to this invention advantageously should reduce the degradation of bendamustine in the patient since the bendamustine is released and dissolved to a major extent while in the stomach.
- bioavailability of the bendamustine containing compositions according to the invention may be expected.
- the oral pharmaceutical compositions may be used for the treatment or prevention of relapse of a medical condition in a human or animal, preferably a human, which medical condition is selected from chronic lymphocytic leukemia (abbreviated as CLL), acute lymphocytic leukaemia (abbreviated as ALL), chronic myelocytic leukaemia (abbreviated as CML), acute myelocytic leukaemiam (abbreviated as AML), Hodgkin's disease, non-Hodgkin's lymphoma (abbreviated as NHL), multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer, non-small cell lung cancer, and an autoimmune disease.
- CLL chronic lymphocytic leukemia
- ALL acute lymphocytic leukaemia
- CML chronic myelocytic leukaemia
- AML acute myelocytic leukaemiam
- NHL non-Hodgkin's lymphoma
- MM multiple my
- the present invention also comprises a method of treatment or prevention of relapse of a medical condition selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer, non-small cell lung cancer, and an autoimmune disease, in a human or animal body comprising administering to the human or animal body in need thereof an effective amount of the pharmaceutical preparation of this invention.
- a medical condition selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer, non-small cell lung cancer, and an autoimmune
- the pharmaceutical composition may be administered in combination with at least one further active agent, wherein said further active agent is given prior, concurrently, or subsequently to the administration of the pharmaceutical composition.
- This at least one further active agent is preferably an antibody specific for CD20 (an examples is rituximab or ofatumumab), an anthracyclin derivative (an example is doxorubicin or daunorubicin), a vinca alkaloid (an example is vincristine), a platin derivative (an example is cisplatin or carboplatin), daporinad (FK866), YM155, thalidomide and analogues thereof (an example is lenalidomide), or a proteasome inhibitor (an example is bortezumib).
- an antibody specific for CD20 an examples is rituximab or ofatumumab
- an anthracyclin derivative an example is doxorubicin or daunorubicin
- the pharmaceutical composition of this invention may also be administered in combination with at least one corticosteroid, wherein said corticosteroid is given prior, concurrently, or subsequently to the administration of the pharmaceutical composition.
- corticosteroids are prednisone, prednisolone and dexamethasone.
- compositions according to the present invention further is, that the active ingredient(s), optionally in admixture with one or more excipients, do not need to be provided with a coating in order to further mask the taste of such ingredient and/or to protect the same against possible harmful effects by light and/or moisture such as oxidation, degradation, or to prevent that the subject may experience damage of the oral mucosa, due to the interaction with the active ingredient.
- NP1 4-[6-(2-Chloroethyl)-3,6,7,8-tetra-hydro-3-methyl-imidazo[4,5-h]-[1,4]benzothiazin-2-yl] butanoic acid BM1Dimer: 4- ⁇ 5-[N-(2-Chloroethyl)-N-(2- ⁇ 4-[5-bis(2-chloroethyl)amino-1-methylbenzimidazol-2-yl]butanoyloxy ⁇ ethyl)amino]-1-methylbenzimidazol-2-yl ⁇ butanoic acid BM1EE: 4-[5-[Bis(2-chloroethyl)amino]-1-methyl-benzimidazo-2-yl] butanoic ethyl ester * 2 n.d.: not detectable, i.e. beyond detection limit (area percentage less than 0.05%)
- the blend was transferred to a capsule filling machine (Zanassi AZ 5) and filled into hard gelatine capsules (size 2) (mean mass: 259.5 mg (begin)-255.3 mg (end)) and hypromellose capsules (size 2) (mean mass: 255.8 (begin)-253.4 mg (end)) respectively.
- Capsules were stored at 40° C./75% RH in a closed glass vial.
- the amount of bendamustine hydrochloride as well as of related substances, like degradation products, by-products of synthesis were measured with HPLC (column: Zorbax Bonus-RP, 5 ⁇ m; temperature of column oven: 30° C.; temperature of autosampler: 5° C.; detector: 254 nm).
- Table 2b filled in hypromellose capsules
- 2c filled in gelatine capsules.
- the blend was transferred to a capsule filling machine (Zanassi AZ 5) and filled into hard gelatine capsules (size 2) (mean mass: 257.9 mg (begin)-255.2 mg (end)) and hypromellose capsules (size 2) (mean mass: 261.1 (begin)-257.8 mg (end)) respectively.
- Capsules were stored at 40° C./75% RH in a closed glass vial.
- the amount of bendamustine hydrochloride and of related substances was measured with HPLC, as described above. The results are shown in Table 3b (filled in hypromellose capsules) and 3c (filled in gelatine capsules).
- the blend was transferred to a capsule filling machine (Zanassi AZ 5) and filled into hard gelatine capsules (size 2) (mean mass: 241.3 mg (begin)-244. mg (end)) and hypromellose capsules (size 2) (mean mass: 243.5 (begin)-243. mg (end)) respectively.
- Capsules were stored at 40° C./75% RH in a closed glass vial.
- the amount of bendamustine hydrochloride and of related substances was measured with HPLC, as described above. The results are shown in Table 4b (filled into hypromellose capsules) and 4c (filled in gelatine capsules).
- Cremophor® RH 40 0.68 g of methylparaben, 0.068 g of propylparaben and 0.068 g of butylhydroxytoluene were weighed and dissolved in 6.14 g of ethanol. Cremophor® RH 40 was melted at 40° C. in a sufficient amount. 5.56 g of the ethanolic solution obtained, 36.83 g of the melted Cremophor® RH 40 and 202.82 g of Pluronic® L44 NF were weighed and mixed at 800 rpm using a mechanical stirrer until the mixture became transparent. The mixture was allowed to solidify by placing it at 10° C.
- BM1Dimer 0.02 0.03 BM1EE 0.15 0.15 Individual 0.01 0.03 unknown impurity 25° C./60% RH HP1 0.09 0.07 98.8 99.0 (closed vial) NP1 n.d. n.d. BM1Dimer 0.02 0.03 BM1EE 0.15 0.15 Individual 0.01 0.03 unknown impurity 5° C. HP1 0.09 0.07 98.8 99.8 (closed vial) NP1 n.d. n.d. BM1Dimer 0.02 0.02 BM1EE 0.15 0.15 Individual 0.01 n.d. unknown impurity
- Cremophor® RH 40 0.68 g of methylparaben, 0.068 g of propylparaben and 0.068 g of butylhydroxytoluene were weighed and dissolved in 6.14 g of ethanol. Cremophor® RH 40 was melted at 40° C. in a sufficient amount. 5.56 g of the ethanolic solution obtained and 239.65 g of the melted Cremophor® RH 40 were weighed and mixed at 800 rpm using a mechanical stirrer until the mixture became transparent. The mixture was allowed to solidify and cool to room temperature.
- the liquid filled capsules so obtained were stored in closed amber glass bottles with screw plugs at 40° C./75% RH, at 30° C./65% RH, at 25° C./60% RH and at 5° C.
- the amount of bendamustine hydrochloride as well as of related substances, like degradation products, by-products of synthesis was measured with HPLC, as described above.
- BM1Dimer 0.03 0.04 BM1EE 0.16 0.13 Individual 0.02 0.03 unknown impurity 25° C./60% RH HP1 0.08 0.10 100.1 100.3 (closed vial) NP1 0.01 n.d. BM1Dimer 0.03 0.03 BM1EE 0.16 0.14 Individual 0.02 0.02 unknown impurity 5° C. HP1 0.08 0.09 100.1 99.5 (closed vial) NP1 0.01 0.01 BM1Dimer 0.03 0.03 BM1EE 0.16 0.15 Individual 0.02 0.02 unknown impurity
- BM1Dimer 0.03 0.09 BM1EE 0.15 0.17 Individual 0.03 0.04 unknown impurity 25° C./60% RH HP1 0.08 0.11 99.6 100.0 (closed vial) NP1 n.d. n.d. BM1Dimer 0.03 0.09 BM1EE 0.15 0.17 Individual 0.03 0.04 unknown impurity 5° C. HP1 0.08 0.07 99.60 100.1 (closed vial) NP1 n.d. 0.01 BM1Dimer 0.03 0.03 BM1EE 0.15 0.15 Individual 0.03 0.02 unknown impurity
- the dissolution test was conducted according to Chapter 2.9.3. of European Pharmacopoeia 6.0, using Apparatus 2 (Paddle-apparatus). The rotation speed of the paddle was 50 rpm, the temperature was 37° C. ⁇ 0.5° C., the amount of dissolution medium was 500 ml.
- liquid filled hard capsule formulation of example 2 according to the invention shows the preferred fast dissolution profile of bendamustine, which is at least 60% in 10 minutes, 70% in 20 minutes and 80% in 30 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of an artificial gastric fluid.
- the liquid filled hard capsules of example 2 containing 50 mg of bendamustine, were orally administered to male and female beagle dogs in comparison with the capsules of reference example 1 in order to determine the bioavailability of 1 dose (i.e. 50 mg) of bendamustine (AUC and Cmax) and to determine the level of variability in bioavailability of these capsule formulations: (i.e. % CV on AUC and Cmax).
- a further formulation (formulation X) was also included in the test but since this formulation was outside the scope of the present invention no details are provided.
- the total number of animals required was 16.
- the basic study design was a cross-over design with 8 animals per arm.
- Period 1 Single Dose of Capsule, Day 1:
- Period 2 (1 Week after Period 1, Single Dose of Either of the Following Formulations, Day 8):
- the mean plasma profiles vs. time for both the capsule formulation (reference example 1) and the liquid filled capsule formulation of Example 2 are shown in FIG. 1 .
- bendamustine HCl 100 mg intravenous, 110.2 mg orally was selected based on the safety of the oral formulation in preclinical studies and based on the safety of the registered i.v. formulation.
- the total duration of the admission period was 6 days (day ⁇ 1 to 2 and day 7-9) excluding screening and a post study visit.
- the blood concentration-time curve as obtained after evaluating 6 patients is shown in FIG. 2 .
- the mean value for the absolute bioavailability, calculated as AUC oral /dose/AUC iv /dose*100% was 58.5%, with a standard deviation of 9.3 and an interindividual variation (expressed as % CV) of 15.9.
- compositions according to the present invention show many advantages. They can be easily used by the patient without assistance of supervisory medical staff. Hence the time-consuming trips to the hospital may become obsolete, thereby increasing the patient compliance. Further there is the advantage that hospital staff is less exposed to the contact with the cytotoxic material, thereby decreasing occupational hazards. Also there is less environmental hazard, as no vials containing the cytotoxic compound need to be discarded.
- the dosage forms can be swallowed as such, which means that the patient does not need to wait until dissolution of the active ingredient has been achieved. On top of that swallowing the medication is a preferred way of taking it, in order to avoid any contact of the active ingredient with the oral mucosa. Further due to the good stability of the dosage forms they can be easily stored at room temperature and without the need of any special storage conditions.
- the dosage forms according to the present invention By using the dosage forms according to the present invention, a considerable reduction of the volume of the dosage form may be achieved.
- the reduced size is desirable both from a manufacturing and handling standpoint and patient compliance.
- compositions show a high dissolution in vitro which should reduce the degradation of bendamustine in vivo.
- inventive compositions may show an improved bioavailability profile of the bendamustine in vivo, as compared to prior art oral formulations.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08075915.2 | 2008-12-03 | ||
EP08075915 | 2008-12-03 | ||
PCT/EP2009/008857 WO2010063493A1 (en) | 2008-12-03 | 2009-12-03 | Oral dosage forms of bendamustine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/008857 A-371-Of-International WO2010063493A1 (en) | 2008-12-03 | 2009-12-03 | Oral dosage forms of bendamustine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/932,785 Continuation US20140018334A1 (en) | 2008-12-03 | 2013-07-01 | Oral Dosage Forms of Bendamustine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120003305A1 true US20120003305A1 (en) | 2012-01-05 |
Family
ID=40588059
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/132,263 Abandoned US20120003305A1 (en) | 2008-12-03 | 2009-12-03 | Oral Dosage Forms Of Bendamustine |
US13/932,785 Abandoned US20140018334A1 (en) | 2008-12-03 | 2013-07-01 | Oral Dosage Forms of Bendamustine |
US14/695,527 Abandoned US20150335588A1 (en) | 2008-12-03 | 2015-04-24 | Oral Dosage Forms of Bendamustine |
US15/174,467 Active US10543196B2 (en) | 2008-12-03 | 2016-06-06 | Oral dosage forms of bendamustine |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/932,785 Abandoned US20140018334A1 (en) | 2008-12-03 | 2013-07-01 | Oral Dosage Forms of Bendamustine |
US14/695,527 Abandoned US20150335588A1 (en) | 2008-12-03 | 2015-04-24 | Oral Dosage Forms of Bendamustine |
US15/174,467 Active US10543196B2 (en) | 2008-12-03 | 2016-06-06 | Oral dosage forms of bendamustine |
Country Status (25)
Country | Link |
---|---|
US (4) | US20120003305A1 (es) |
EP (1) | EP2367542B1 (es) |
JP (1) | JP5778037B2 (es) |
KR (1) | KR101688038B1 (es) |
CN (2) | CN102281871A (es) |
AU (1) | AU2009321745B2 (es) |
BR (1) | BRPI0922806B8 (es) |
CA (1) | CA2745525A1 (es) |
CO (1) | CO6400183A2 (es) |
CY (1) | CY1114977T1 (es) |
DK (1) | DK2367542T3 (es) |
EA (1) | EA020354B1 (es) |
ES (1) | ES2451540T3 (es) |
HR (1) | HRP20140204T1 (es) |
IL (1) | IL213270A (es) |
MX (1) | MX2011005643A (es) |
NZ (1) | NZ592970A (es) |
PL (1) | PL2367542T3 (es) |
PT (1) | PT2367542E (es) |
RS (1) | RS53201B (es) |
SI (1) | SI2367542T1 (es) |
SM (1) | SMT201400053B (es) |
UA (1) | UA102120C2 (es) |
WO (1) | WO2010063493A1 (es) |
ZA (1) | ZA201103791B (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8809549B2 (en) | 2012-04-26 | 2014-08-19 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
US20150258070A1 (en) * | 2010-06-02 | 2015-09-17 | Astellas Deutschland Gmbh | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof |
US9849115B2 (en) | 2013-08-27 | 2017-12-26 | Vasilios Voudouris | Bendamustine pharmaceutical compositions |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103037851A (zh) | 2010-06-02 | 2013-04-10 | 安斯泰来德国有限公司 | 苯达莫司汀的口服剂型 |
CN102375044B (zh) * | 2010-08-18 | 2015-04-08 | 重庆华邦胜凯制药有限公司 | 一种盐酸苯达莫司汀中间体z6有关物质的分析方法 |
CN104011029B (zh) * | 2011-09-26 | 2016-06-08 | 费森尤斯卡比肿瘤学有限公司 | 一种制备盐酸苯达莫司汀的改进方法 |
MX363226B (es) | 2011-10-31 | 2019-03-15 | Genentech Inc | Formulaciones de anticuerpos. |
EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
EA029706B1 (ru) * | 2012-11-12 | 2018-05-31 | Игнайта, Инк. | Сложные алкиловые эфиры бендамустина и способы их применения |
EP3135276B1 (en) * | 2013-03-12 | 2019-05-08 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
JP2016153374A (ja) * | 2013-06-25 | 2016-08-25 | シンバイオ製薬株式会社 | 炎症性疾患を治療又は予防するための医薬組成物 |
BR112020006360A2 (pt) | 2017-10-05 | 2020-09-24 | Tube Pharmaceuticals Gmbh | composição para uso como um medicamento e composição farmacêutica oral que compreendem bendamustina ou um sal ou solvato farmaceuticamente aceitáveis, uso e método de distribuição de bendamustina ou um sal ou solvato farmaceuticamente aceitáveis, método de tratamento de uma doença ou disfunção em um sujeito com necessidade do mesmo |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US132502A (en) * | 1872-10-22 | Improvement in machines for removing snow from railroads | ||
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
EP1814544A4 (en) * | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
CN101052396A (zh) * | 2004-11-05 | 2007-10-10 | 赛福伦公司 | 癌症治疗 |
US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
CN101119708B (zh) * | 2005-01-14 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀冻干药物组合物 |
CN101028249A (zh) * | 2007-04-12 | 2007-09-05 | 济南康泉医药科技有限公司 | 一种含新生血管抑制剂及烷化剂的抗癌组合物 |
CN101045058A (zh) * | 2007-04-28 | 2007-10-03 | 济南帅华医药科技有限公司 | 一种含烷化剂及激素类药物的抗癌组合物 |
CN101084876A (zh) * | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
US20090130198A1 (en) * | 2007-11-21 | 2009-05-21 | Innopharmax Inc. | Pharmaceutical composition with enhanced bioavailability |
US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
-
2009
- 2009-12-03 UA UAA201106235A patent/UA102120C2/ru unknown
- 2009-12-03 BR BRPI0922806A patent/BRPI0922806B8/pt active IP Right Grant
- 2009-12-03 SI SI200930877T patent/SI2367542T1/sl unknown
- 2009-12-03 PL PL09796303T patent/PL2367542T3/pl unknown
- 2009-12-03 CN CN2009801547145A patent/CN102281871A/zh active Pending
- 2009-12-03 DK DK09796303.7T patent/DK2367542T3/da active
- 2009-12-03 PT PT97963037T patent/PT2367542E/pt unknown
- 2009-12-03 RS RS20140111A patent/RS53201B/en unknown
- 2009-12-03 KR KR1020117015292A patent/KR101688038B1/ko active IP Right Grant
- 2009-12-03 ES ES09796303.7T patent/ES2451540T3/es active Active
- 2009-12-03 JP JP2011538906A patent/JP5778037B2/ja active Active
- 2009-12-03 AU AU2009321745A patent/AU2009321745B2/en active Active
- 2009-12-03 CN CN201510849775.0A patent/CN105363037B/zh active Active
- 2009-12-03 MX MX2011005643A patent/MX2011005643A/es active IP Right Grant
- 2009-12-03 EA EA201190011A patent/EA020354B1/ru unknown
- 2009-12-03 WO PCT/EP2009/008857 patent/WO2010063493A1/en active Application Filing
- 2009-12-03 NZ NZ592970A patent/NZ592970A/xx unknown
- 2009-12-03 EP EP09796303.7A patent/EP2367542B1/en active Active
- 2009-12-03 US US13/132,263 patent/US20120003305A1/en not_active Abandoned
- 2009-12-03 CA CA2745525A patent/CA2745525A1/en not_active Abandoned
-
2011
- 2011-05-24 ZA ZA2011/03791A patent/ZA201103791B/en unknown
- 2011-05-31 IL IL213270A patent/IL213270A/en active IP Right Grant
- 2011-06-28 CO CO11080792A patent/CO6400183A2/es not_active Application Discontinuation
-
2013
- 2013-07-01 US US13/932,785 patent/US20140018334A1/en not_active Abandoned
-
2014
- 2014-03-05 CY CY20141100174T patent/CY1114977T1/el unknown
- 2014-03-05 HR HRP20140204AT patent/HRP20140204T1/hr unknown
- 2014-04-22 SM SM201400053T patent/SMT201400053B/xx unknown
-
2015
- 2015-04-24 US US14/695,527 patent/US20150335588A1/en not_active Abandoned
-
2016
- 2016-06-06 US US15/174,467 patent/US10543196B2/en active Active
Non-Patent Citations (4)
Title |
---|
Katdare et al. Excipient Development for Pharmaceutical, Biotechnology and Drug Delivery Systems, First Edition, , 2006, Chapter 13, (pages 197-223) * |
Katdare et al. Excipient Development for Pharmaceutical, Biotechnology and Drug Delivery Systems, First Edition, 2006, Chapter 11 (pages 155-180) * |
Martin Siewert, FIP Guidelines for Dissolution Testing of Solid Oral Products, 1995, Pharm. Ind. 57(5), 362-369 * |
Vippagunta et al. "Crystalline Solids," Advanced Drug Delivery Reviews, 2001, 48, pp. 18 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150258070A1 (en) * | 2010-06-02 | 2015-09-17 | Astellas Deutschland Gmbh | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof |
US10485787B2 (en) * | 2010-06-02 | 2019-11-26 | Astellas Deutschland Gmbh | Oral dosage forms of bendamustine and therapeutic use thereof |
US8809549B2 (en) | 2012-04-26 | 2014-08-19 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
US9849115B2 (en) | 2013-08-27 | 2017-12-26 | Vasilios Voudouris | Bendamustine pharmaceutical compositions |
US10786486B2 (en) | 2013-08-27 | 2020-09-29 | Vasilios Voudouris | Bendamustine pharmaceutical compositions |
US11701344B2 (en) | 2013-08-27 | 2023-07-18 | Vasilios Voudouris | Bendamustine pharmaceutical compositions |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10543196B2 (en) | Oral dosage forms of bendamustine | |
US10485787B2 (en) | Oral dosage forms of bendamustine and therapeutic use thereof | |
JP6373300B2 (ja) | ベンダムスチンの経口投与形 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASTELLAS DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLLEDGE, JEFFREY;OLTHOFF, MARGARETHA;SIGNING DATES FROM 20110817 TO 20110905;REEL/FRAME:026933/0711 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |